Vortioxetine for Post-COVID-19 Condition

PHASE2CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

February 22, 2023

Study Completion Date

February 22, 2023

Conditions
Post-COVID-19 ConditionPost-COVID-19 SyndromeCognitive Impairment
Interventions
DRUG

Vortioxetine

"Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician."

DRUG

Placebo

A placebo pill will be taken once daily.

Trial Locations (1)

M5S 1M2

Brain and Cognition Discovery Foundation (BCDF), Toronto

All Listed Sponsors
lead

Brain and Cognition Discovery Foundation

OTHER

NCT05047952 - Vortioxetine for Post-COVID-19 Condition | Biotech Hunter | Biotech Hunter